MDT-AP-3328
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 7.9
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.261812779
- umap2_2d
- -0.027330469
- umap1_3d
- -1.244033121
- umap2_3d
- -2.891510468
- umap3_3d
- -1.327648151
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- MYC_TARGETS_V1+0.510
- INTERFERON_ALPHA_RESPONSE+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- MTORC1_SIGNALING+0.390
- G2M_CHECKPOINT+0.370
- PROTEIN_SECRETION+0.330
- ANDROGEN_RESPONSE+0.320
- E2F_TARGETS+0.320
Top 10 suppressed
- XENOBIOTIC_METABOLISM-0.290
- MYOGENESIS-0.270
- ESTROGEN_RESPONSE_LATE-0.260
- KRAS_SIGNALING_DN-0.220
- COAGULATION-0.200
- BILE_ACID_METABOLISM-0.190
- APICAL_JUNCTION-0.170
- HYPOXIA-0.160
- PANCREAS_BETA_CELLS-0.160
- COMPLEMENT-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.868 |
| 2 | MNG1211 | — | — | 0.856 |
| 3 | SRR934975 | — | — | 0.855 |
| 4 | SRR934878 | — | — | 0.851 |
| 5 | SRR934930 | — | — | 0.846 |
| 6 | SRR934964 | — | — | 0.845 |
| 7 | sclcMAD13022_S60.txt | — | cohortMD1 | 0.840 |
| 8 | SRR934882 | — | — | 0.840 |
| 9 | E0173AAB-678A-46E0-B701-C79A6BE9B9D8 | — | — | 0.838 |
| 10 | SRR934851 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |